Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 3/20 | 0.58 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17936605 | 0.88 | PDE7A (0.56) | PDE7APDE7BSMN1; SMN2MAPTGAA | |
| SCHEMBL16416583 | 0.84 | NPC1 (0.54) | PDE7APDE7BSMN1; SMN2MAPTNPC1 | |
| SCHEMBL16591377 | 0.82 | LMNA (0.56) | PDE7APDE7BSMN1; SMN2MAPTGAA | |
| SCHEMBL16591383 | 0.81 | PIK3CD (0.47) | PDE7APDE7BSMN1; SMN2MAPTGAA | |
| SCHEMBL16591392 | 0.80 | PIK3CD (0.49) | — | |
| SCHEMBL16591389 | 0.80 | TRPV4 (0.45) | PDE7APDE7BSMN1; SMN2MAPTGAA | |
| SCHEMBL5928786 | 0.79 | KDM4E (0.63) | SMN1; SMN2MAPTGAANPC1RAB9A | |
| SCHEMBL15836366 | 0.79 | MAPT (0.58) | PDE7APDE7BSMN1; SMN2MAPTGAA | |
| SCHEMBL30122631 | 0.78 | MAPK1 (0.75) | SMN1; SMN2ALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL1682746 | 0.78 | MAPK1 (0.75) | SMN1; SMN2ALDH1A1KDM4EPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160207929-A1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | RHIZEN PHARMACEUTICALS SA (CH) | 2016-07-21 | — | — | US | disclosed |
| US-8278327-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110021509-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-01-27 | — | — | US | disclosed |
| US-7786139-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080300240-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300240-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | PDE7A 3/4885PDE7B 23/4885SMN1; SMN2 600/4885 |
| US-20160207929-A1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | PRKCZ, PRKCE, PRKCA | PDE7A 816/4885PDE7B 1167/4885SMN1; SMN2 2820/4885 |
| US-20110021509-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | PDE7A 3/4885PDE7B 25/4885SMN1; SMN2 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.